Collaboration in Managing Targeted Therapy for HR-Positive HER2-Negative Breast Cancer

/ Collaboration in Managing Targeted Therapy for HR-Positive HER2-Negative Breast Cancer

Case 3: Managing Toxicity to Maintain Long-Term Benefit

This is Part 3 of Shared Decisions, Better Outcome: Collaboration in Managing Targeted Therapy for HR-Positive/HER2-Negative Breast Cancer, a three-part video roundtable series. Scroll down to watch t...

breast cancer

/ Collaboration in Managing Targeted Therapy for HR-Positive HER2-Negative Breast Cancer

Case 2: Promoting Adherence Through Early Management Strategies

This is Part 2 of Shared Decisions, Better Outcome: Collaboration in Managing Targeted Therapy for HR-Positive/HER2-Negative Breast Cancer, a three-part video roundtable series. Scroll down to watch t...

breast cancer

/ Collaboration in Managing Targeted Therapy for HR-Positive HER2-Negative Breast Cancer

Case 1: Treatment Considerations at Disease Progression on CDKi

This is Part 1 of Shared Decisions, Better Outcome: Collaboration in Managing Targeted Therapy for HR-Positive/HER2-Negative Breast Cancer, a three-part video roundtable series. Scroll down to watch t...

Collaboration in Managing Targeted Therapy for HR-Positive HER2-Negative Breast Cancer

Case 3: Managing Toxicity to Maintain Long-Term Benefit

Case 2: Promoting Adherence Through Early Management Strategies

Case 1: Treatment Considerations at Disease Progression on CDKi

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma

AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans